Details for Patent: 11,453,656
✉ Email this page to a colleague
Which drugs does patent 11,453,656 protect, and when does it expire?
Patent 11,453,656 protects LAZCLUZE and is included in one NDA.
This patent has thirty patent family members in twenty-two countries.
Drugs Protected by US Patent 11,453,656
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-001 | Aug 19, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-002 | Aug 19, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,453,656
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 111469 | ⤷ Subscribe | |||
Australia | 2018256227 | ⤷ Subscribe | |||
Australia | 2022203486 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |